Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Dupilumab is a human monoclonal antibody ... was developed by the trial sponsors (Sanofi and Regeneron Pharmaceuticals) and three of the authors. Data were collected by the investigators and ...

The safety profile of dupilumab was consistent with that observed in previous clinical trials. Adverse events ... President and Chief Scientific Officer at Regeneron, and a principal inventor ...

“Our higher target reflects confidence in Dupilumab’s commercial COPD opportunity, adding to our already positive outlook for Regeneron on an ophthalmology franchise renewed by 8mg ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

A pivotal phase 3 trial of dupilumab (Dupixent ... The topline results were announced in a release by Sanofi and Regeneron, which said more complete results will be presented in an upcoming ...

Sanofi and Regeneron said that drug candidate didn’t meet primary endpoint in a phase three study, although a benefit was ...

Data from prior Sanofi/Regeneron studies further supports ... on high-dose ICS plus placebo. The VESTIGE trial, meanwhile, demonstrated that dupilumab led to reductions in mucus plugging and ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and ...